



CardieX's ATCOR Technology Chosen for Yale University Clinical Trial

ATCOR's SphygmoCor® XCEL System to be Used in Yale University Clinical Trial focused on Maternal Health

24 June 2021: Australian medical technology company CardieX announced that its subsidiary, ATCOR's SphygmoCor® XCEL System has been selected for a clinical trial being conducted by Yale University, [Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension \(ASPPIRE\)](#).

The trial, which is currently recruiting, will test the effectiveness of aspirin for the prevention of pre-eclampsia in women with elevated blood pressure, using ATCOR's SphygmoCor® XCEL device to non-invasively measure central blood pressure, central arterial pressure waveform, and pulse wave velocity, as well as other heart health parameters of participants.

Hypertension during pregnancy is an indicator of severe maternal morbidity and a preventable condition [affecting an estimated 6.5% of women](#). ATCOR's technology will provide additional data on the cardiovascular health of women enrolled in the study and support the trial's safety.

CardieX CEO Craig Cooper said:

"We've been heavily focused on broadening the reach of our patented central blood pressure monitoring technology and being chosen by Yale for this unique study is a significant validation of our efforts. We see a significant opportunity in the maternal blood pressure market going forward with our new devices. Our plan is to have our upcoming Pulse dual blood pressure monitor validated for home use for pregnant women, a market that has traditionally been neglected by medical device companies in the past who have focused solely on hypertension. Having our devices validated for pregnant women will allow us to target the upwards of 4 million pregnant women yearly in the USA and provide better solutions for women at risk of pre-eclampsia".

This announcement shortly follows CardieX's ATCOR also benefiting from the \$40.5 million Australian federal budget allocation for ambulatory blood pressure monitoring Medicare rebates.

"The Medicare rebate will now give physicians a financial incentive to prescribe the Oscar 2 with SphygmoCor** device in the treatment and management of blood pressure" Cooper said.



For more information please contact:

Investor Relations:

Rod Hinchcliffe rod.hinchcliffe@mcpartners.com.au

Media Relations:

Melissa Hamilton melissa.hamilton@mcpartners.com.au

About CardieX

CardieX is a global health technology company. Its ATCOR subsidiary is a world leader in medical devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders. Its CONNEQT subsidiary develops and markets consumer home health devices and wearables. CardieX is listed on the Australian Stock Exchange (ASX:CDX).

** Oscar 2 with SphygmoCor® is an ambulatory blood pressure monitor (ABPM) developed in partnership with SunTech Medical.